Efficacy profile of the CYD-TDV dengue vaccine revealed by Bayesian survival analysis of individual-level phase III data

BACKGROUND: Sanofi-Pasteur’s CYD-TDV is the only licensed dengue vaccine. Two phase three trials showed higher efficacy in seropositive than seronegative recipients. Hospital follow-up revealed increased hospitalisation in 2–5- year-old vaccinees, where serostatus and age effects were unresolved. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Laydon, Daniel J, Dorigatti, Ilaria, Hinsley, Wes R, Nedjati-Gilani, Gemma, Coudeville, Laurent, Ferguson, Neil M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2021
Materias:
Epidemiology and Global Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321579/
https://www.ncbi.nlm.nih.gov/pubmed/34219653
http://dx.doi.org/10.7554/eLife.65131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321579/
https://www.ncbi.nlm.nih.gov/pubmed/34219653
http://dx.doi.org/10.7554/eLife.65131

Ejemplares similares